Goldline Pharmaceutical IPO 2026: Dates, price band, GMP

Subscription window opens on 12 May

Goldline Pharmaceutical, a pharma-sector company, is set to open its SME IPO subscription window on 12 May 2026. The issue closes on 14 May 2026, with the company targeting a fundraise of ₹11.61 crore through the offering. The IPO is proposed to be listed on the BSE SME platform, making it part of the growing pipeline of smaller issuers tapping public markets.

The offer is structured as a book-built issue and is entirely a fresh issue, meaning all proceeds go to the company rather than selling shareholders. Investors tracking the deal are also watching grey market indicators, which have been cited across sources in the provided material. While GMP is unofficial and volatile, it is being used as an early sentiment gauge ahead of subscription data.

Goldline Pharmaceutical IPO key dates

The IPO timeline disclosed across the provided details includes the subscription period, allotment date, and a tentative listing schedule. Allotment is expected to be finalised shortly after the issue closes, followed by refund initiation and demat credit.

A clear schedule is important for investors planning UPI mandate windows or ASBA bids, particularly because the ticket size for this SME issue is higher due to the lot structure. The listing is expected in the week immediately following allotment.

Issue size and structure: fresh issue of 27 lakh shares

Goldline Pharmaceutical’s IPO is a fresh issue of 27,00,000 equity shares. The total issue size is stated as ₹11.61 crore in the provided material. Since it is a fresh issue only, the company will receive the proceeds (net of issue expenses) for stated corporate purposes.

The material also mentions market maker participation, including a specific quantity of market maker shares offered. The market maker function is typically used in SME listings to support liquidity after listing.

Price band, lot size, and minimum application amount

The IPO price band is set at ₹41 to ₹43 per share. The lot size is 3,000 shares per lot. As per the provided details, a retail application requires a minimum of 2 lots, or 6,000 shares.

At the upper price band of ₹43, the minimum retail investment works out to ₹2.58 lakh for 6,000 shares. For HNI/NII applicants, the minimum application indicated is 3 lots, or 9,000 shares, which translates to about ₹3.87 lakh at the upper band.

These high minimum ticket sizes are a defining feature for several SME issues, and they often shape participation across investor categories. Investors typically plan applications accordingly to match capital availability and risk limits.

GMP in focus: ₹16-₹17 cited ahead of opening

In the unlisted market, the Grey Market Premium (GMP) cited in the provided text ranges around ₹16 to ₹17 as of 11 May 2026. One line states GMP at ₹17, described as about 39.5% above the cap price, while another states the GMP stands at ₹16 (37%).

Based on the note that ₹16 GMP implies an estimated listing price of around ₹58-₹59 per share (using an upper band of ₹43), the market is signalling positive early sentiment. However, the same material also flags that GMP is an unofficial indicator and does not guarantee listing gains. Since subscription data is stated to be updated after the IPO opens, investors will only get verified demand numbers from 12 May 2026 onward.

Category-wise reservation and share allocation snapshot

The provided material includes a category-wise allocation table with both percentages and share counts. It lists the following split out of the total 27,00,000 shares.

• Anchor: 27.11% (7,32,000 shares)
• QIB: 20.00% (5,40,000 shares)
• HNI: 14.44% (3,90,000 shares)
• Retail: 33.33% (9,00,000 shares)
• Market Maker: 5.11% (1,38,000 shares)

This allocation provides a quick view of how the issue is distributed and what portion is earmarked for retail investors. Demand trends across these buckets are typically tracked during the three-day subscription window once bids begin.

Where the IPO money will be used

Goldline Pharmaceutical plans to use a large portion of the IPO proceeds to reduce debt. According to the documents cited in the provided text, about ₹8.35 crore is intended for repayment or prepayment of existing borrowings.

The remaining amount is to be used for general corporate purposes and to strengthen business operations. For investors, the stated focus on debt reduction is a key use-of-funds detail because it directly affects leverage and interest cost, though actual impact depends on the company’s broader financial profile which is not detailed in the provided text.

Key intermediaries: lead manager, registrar, market maker

The book running lead manager for the issue is Cumulative Capital Private Limited. Bigshare Services Private Limited is the registrar for the IPO, and Nirman Share Brokers Private Limited is named as the market maker.

The registrar’s platform is also where investors can typically check allotment status after finalisation. The material states allotment status will be available on 15 May 2026, and that investors can check using PAN, application number, or DP ID on registrar sites and exchange platforms.

How to check allotment and track updates

Based on the provided information, allotment is expected on 15 May 2026. Investors can check the status on the registrar’s website, and the material references checks via PAN, application number, or DP ID.

The same timeline indicates refunds and demat credit on 18 May 2026, followed by listing on 19 May 2026. Until the IPO opens, subscription figures remain unavailable, and the provided text explicitly notes that subscription updates will begin after 12 May 2026.

Key IPO details at a glance

What to watch as bidding begins

With the issue opening on 12 May 2026, the most important next data point will be the live subscription numbers across QIB, HNI, and retail categories. The provided material repeatedly notes that subscription status will be updated once bidding begins.

For investors, the combination of a debt-repayment-heavy use of proceeds, a defined SME lot structure, and an active grey market quote sets the near-term discussion points. The next confirmed milestones are allotment on 15 May and the tentative listing on 19 May 2026 on the BSE SME platform.